ROIV
Roivant Sciences Ltd.Roivant Sciences Ltd. reported revenue of $8.26M in its most recent fiscal year, down 71.6% on the year before. It kept -3629.2% of that as net income, and generated -$758.56M of free cash flow. Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | -71.6% | 12.8% | — |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | -36.0% | 12.2% | — |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | -19.1% | 12.5% | — |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | Not reported | -1.4% | — |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | 0.6% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | 0.0% | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | Not reported | -4.1% | — |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 1.4% | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 70.7% | — |
Operating margin Operating income as a share of revenue. | -6235.7% | -15.3% | — |
Net margin Net income as a share of revenue. | -3629.2% | -13.0% | — |
Free cash flow margin Free cash flow as a share of revenue. | -9183.5% | -2.0% | — |
Return on equity Net income divided by shareholder equity. | -6.6% | -14.2% | — |
Return on assets Net income divided by total assets. | -5.3% | -9.5% | — |
Return on invested capital After-tax operating profit over debt plus equity less cash. | -13.1% | -6.1% | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | Not reported | 0.43x | — |
Current ratio Current assets over current liabilities. | 18.37x | 2.96x | — |
Quick ratio Current assets excluding inventory, over current liabilities. | 18.37x | 2.58x | — |
Interest coverage Operating income divided by interest expense. | Not reported | -0.74x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.25x | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 40 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 20, 2026 | Venker Eric President & Immunovant CEO | Open-market sale | 185,856 | $35.09 | $6.52M |
| Oct 20, 2026 | Venker Eric President & Immunovant CEO | Open-market sale | 14,144 | $35.42 | $501.0K |
| Oct 16, 2026 | Gline Matthew CEO | Withheld for tax | 34,638 | $33.53 | $1.16M |
| Oct 16, 2026 | Sukhatme Mayukh President & CIO | Withheld for tax | 19,976 | $33.53 | $669.8K |
| Oct 1, 2026 | Epperly Melissa B, Director | Open-market sale | 16,850 | $36.08 | $607.9K |
| Oct 1, 2026 | Epperly Melissa B, Director | Option exercise | 17,750 | $4.46 | $79.2K |
| Oct 1, 2026 | Epperly Melissa B, Director | Open-market sale | 900 | $36.57 | $32.9K |
| Oct 1, 2026 | Epperly Melissa B, Director | Option exercise(derivative) | 17,750 | $0.00 | $0.00 |
| Sep 30, 2026 | Venker Eric President & Immunovant CEO | Open-market sale | 200,000 | $36.62 | $7.32M |
| Sep 30, 2026 | Gline Matthew CEO | Withheld for tax | 76,171 | $36.57 | $2.79M |
| Sep 30, 2026 | Sukhatme Mayukh President & CIO | Withheld for tax | 46,879 | $36.57 | $1.71M |
| Sep 30, 2026 | Torti Frank President and Vant Chair | Withheld for tax | 40,309 | $36.57 | $1.47M |
| Sep 30, 2026 | Venker Eric President & Immunovant CEO | Option exercise | 200,000 | $3.85 | $770.0K |
| Sep 30, 2026 | Venker Eric President & Immunovant CEO | Option exercise(derivative) | 200,000 | $0.00 | $0.00 |
| Sep 20, 2026 | Humes Jennifer Chief Accounting Officer | Withheld for tax | 3,880 | $39.77 | $154.3K |
| Sep 20, 2026 | Pulik Richard CFO | Withheld for tax | 2,129 | $39.77 | $84.7K |
| Sep 16, 2026 | MOMTAZEE JAMES C Director | Grant or award | 5,054 | $0.00 | $0.00 |
| Sep 16, 2026 | MOMTAZEE JAMES C Director | Grant or award(derivative) | 10,531 | $0.00 | $0.00 |
| Sep 16, 2026 | MANCHESTER KEITH S Director | Grant or award | 5,054 | $0.00 | $0.00 |
| Sep 16, 2026 | MANCHESTER KEITH S Director | Grant or award(derivative) | 10,531 | $0.00 | $0.00 |
| Sep 16, 2026 | Fitzgerald Meghan Director | Grant or award | 5,054 | $0.00 | $0.00 |
| Sep 16, 2026 | Fitzgerald Meghan Director | Grant or award(derivative) | 10,531 | $0.00 | $0.00 |
| Sep 16, 2026 | Oren Ilan Director | Grant or award | 5,054 | $0.00 | $0.00 |
| Sep 16, 2026 | Oren Ilan Director | Grant or award(derivative) | 10,531 | $0.00 | $0.00 |
| Sep 16, 2026 | Gold Daniel Allen Director | Grant or award | 5,054 | $0.00 | $0.00 |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 Mar | 2024 Mar | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $8.26M | $29.05M | $32.71M | $31.53M | $55.29M | $23.80M |
| Operating income | -$515.07M | -$1.00B | $4.50B | -$906.76M | -$1.35B | -$1.07B |
| Net income | -$299.77M | -$171.98M | $4.35B | -$1.01B | -$845.26M | -$809.23M |
| EPS (diluted) | -$0.54 | -$0.24 | $5.23 | -$1.42 | -$1.26 | -$1.28 |
| Operating cash flow | -$750.35M | -$839.45M | -$765.27M | -$843.39M | -$677.73M | -$552.14M |
| Capital expenditure | $8.21M | $4.60M | $1.38M | $12.69M | $17.44M | $5.81M |
| Free cash flow | -$758.56M | -$844.05M | -$766.65M | -$856.08M | -$695.16M | -$557.94M |
| Total assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B | $2.59B |
| Shareholder equity | $4.53B | $4.69B | $5.97B | $1.16B | $1.66B | $1.80B |
| Total debt | — | — | $442.59M | $416.24M | $210.03M | $170.28M |
| Cash | $1.42B | $2.72B | $6.49B | $1.68B | $2.06B | $2.06B |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Source
Figures come from Roivant Sciences Ltd.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed May 20, 2026. View filings on EDGAR.